3 citations
,
October 1995 in “International Journal of Dermatology” Finasteride helps treat skin issues like acne and baldness by blocking testosterone conversion.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
32 citations
,
July 2016 in “PubMed” 5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
32 citations
,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
Eriocitrin and silymarin might be effective for hair loss treatment and need more research.
4 citations
,
January 1982 in “Endocrinologia Japonica” Androgens regulate 5 alpha-reductase activity in hamster sebaceous glands.
13 citations
,
December 2010 in “Pharmacology Biochemistry and Behavior” Inhibiting certain enzymes made female rats more sensitive to low-level pain.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
July 2026 in “Postgraduate Medicine” Finasteride for hair loss often causes depression, with risks outweighing benefits.
3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
3 citations
,
October 1993 in “Endocrinology” 3 citations
,
August 2010 in “Letters in Drug Design & Discovery”
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
66 citations
,
January 2008 in “Pharmacology Biochemistry and Behavior” AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
15 citations
,
May 2009 in “Steroids” Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
27 citations
,
July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology” The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
Baicalin may effectively treat hair loss by inhibiting 5α-reductase.
5 citations
,
February 2017 in “Biomolecules & Therapeutics” 4-O-Methylhonokiol helps protect skin cells from growth-stopping effects of a protein by regulating growth-related pathways.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
11 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
Dutasteride may become the top choice for treating hair loss.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.